SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) today reports 2008 preliminary and unaudited total revenues of $6.9 million. Celution® System and StemSource® product sales accounted for $4.5 million of the total. The Company forecasts 2009 product revenues of at least $10 million. Product revenue in 2009 is expected to be driven primarily by European and Asia-Pacific Celution® System sales to the cosmetic and reconstructive surgery and translational medicine markets. The translational medicine market consists of clinical investigators who purchase systems and consumables for access to clinical grade cells for their own sponsored studies.
